CLONZ is a biopharmaceutical firm promoted by a group of young and passionate Biotechnologists, focused on the development, manufacturing and commercialization of Human Therapeutic biosimilar Monoclonal Antibodies (MAbs). Clonz got incorporated in 2009 and started its operations in September 2010 at Genome Valley, Hyderabad, India With experienced team coming from recognized leaders in recombinant biosimilar manufacturing, Clonz is committed to delivering quality biologics to make treatment and care affordable to the world population in many disease indications, with special emphasis on Oncology.